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INTRODUCTION 
Rectal cancer is the third most commonly diagnosed cancer occurring in both 
males and females globally(1). In India, the incidence of rectal cancer among 
males is higher than females, which is different from the rest of the world. 
Increasing incidence among younger males in India has been seen as a trend (2). 
Low socioeconomic status has been seen to be associated with the incidence of 
rectal cancer both globally and in India (3).  
 
Though the management of rectal cancer is multimodal, adequate surgical 
resection is the mainstay of treatment and is considered the primary treatment 
modality. Rectal resection remains a morbid operation, one of the most 
troublesome complications being pelvic collection. 
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 Pelvic drainage by means of closed tubular drainage has been practised routinely 
with the objective of reducing the post operative morbidity (4). This study aims to 
observe the role of closed tube pelvic drainage in the post operative outcome 
following rectal resection. Although the ineffectiveness of such an intervention in 
reducing postoperative morbidity has been established in patients undergoing small 
intestinal and colonic resections, there is no conclusive data in patients undergoing 
rectal resection. In fact the effectiveness of such an intervention for rectal resection 
has been questioned(5,6). 
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AIM 
To assess the efficacy of pelvic drainage in preventing pelvic collection after 
elective rectal resection for cancer. 
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OBJECTIVES 
 
1. To detect the presence of pelvic collection by ultrasonographic imaging of 
the pelvis on the 5
th
 post operative day and measure its volume if present. 
2. To assess the morbidity in terms of deviation in the normal post operative 
course  
3. To record the number of days of hospital stay according to ‘fit for discharge’ 
criteria *.  
4. To document the occurrence of urinary tract infection (UTI) during the post 
operative period (30 days following surgery). 
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*Fit for discharge criteria are as follows: 
 Have good pain control with oral analgesia; 
 Are taking solid food with no IV fluids; 
 Are independently mobile or at the same level as pre-operatively; 
 Meet all of the above criteria and are willing to go home. 
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REVIEW OF LITERATURE 
 
INTRODUCTION: 
 
Colorectal cancer is an important public health issue. It is the third most 
common cancer among men (10% of all cancer cases) and second most 
common cancer among women (9.4% of all cancer cases) worldwide (7).  
Colorectal cancer is the fourth most common cause of cancer related death 
in the world and accounts for 8% of cancer deaths. The incidence increases 
with increase in age but however, some studies from India have reported 
higher incidence in younger males (8). The mortality rates have been shown 
to be lower in females than in males. The behavior of rectal cancer has been 
found to be similar to colon cancer. Though the pathogenesis of colon and 
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rectal cancer is the same, there are anatomical peculiarities specific to the 
rectum that require a different approach to rectal cancer (9). Unlike colon 
cancer which has higher incidence among higher socioeconomic groups, 
rectal cancer is more common among lower socioeconomic groups. 
 
 
 
BURDEN OF DISEASE: 
 
Colorectal cancer is the fourth most common cause of death worldwide. The 
incidence is found to be higher in western populations (North America, 
Europe, Australia and New Zealand). This trend is gradually being noticed 
in developing countries. Due to the presence of infectious disease and 
maternal mortality in the developing countries, rectal cancer burden is not 
perceived to be significant. However, once an individual crosses the age of 5 
years, the risk attributed to cancer increases proportionately. There has been 
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a marked decline in incidence among females. This may be due to the 
stronger penetration of oral contraceptives and hormone replacement 
therapy. Risk on colorectal cancer in users of oral contraceptives and 
hormone replacement was reduced by 18% and 20% respectively (9). The 
incidence of colon cancer in India varies from 3.7 to 0.7/100,000 in men and 
3 to 0.4/100,000 in women. The incidence of rectal cancer varies from 5.5 to 
1.6/100,000 in men and 2.8 to 0/100,000 in women. The rural incidence 
rates are approximately half the urban incidence rates. There has been 
increasing incidence of rectal cancer among younger Indian males. Although 
there have been increase in incidence rates among males and females for 
colon cancer, the incidence rates for rectal cancer continue to be stable. The 
overall lower incidence of colorectal cancer among Indian population can be 
attributed to increased starch content in the diet and the presence of  natural 
antioxidants (curcumin) (2). 
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NON AVOIDABLE RISK FACTORS: 
 
There seems to be a higher incidence of right colon cancer among females, 
while rectal cancer is more common among males. Older age groups have 
higher incidence of right colon cancers while left colon and rectal cancers 
are higher in younger age groups. Several genetic factors seem to affect the 
age of onset of colorectal cancers. Earlier age of onset is seen in hereditary 
conditions like Familial adenomatous polyposis (FAP) and hereditary non 
polyposis colon cancer (HNPCC). The hypothesis that colorectal cancer, 
both sporadic and hereditary forms develop from premalignant lesions is 
accepted. A family history of colon cancer is another significant non 
avoidable risk factor. Other risk factors include the presence of 
inflammatory bowel disease, pelvic irradiation, history of non cancer 
surgery, history of breast, endometrial and ovarian cancer and no or low 
parity (9). 
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AVOIDABLE RISK FACTORS: 
 
Dietary, lifestyle and environmental factors seem to contribute to difference 
in incidences. High red meat content in diet has been associated with greater 
incidence along with animal fats, proteins and sugars. High fibre diets are 
associated with lower incidence. Relation of energy intake, physical activity, 
metabolism and body mass index with incidence has been found. Other 
controllable lifestyle factors include alcohol consumption, use of tobacco 
and use of hormones in post menopausal women (9–11). 
 
SCREENING: 
Screening for early cancer can reduce the mortality associated with the 
disease significantly. Finding an adenoma and removing it will reduce the 
progression to cancer and the incidence. Survival in colorectal cancer 
increases from 50% to 90% when detected early, before the onset of 
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symptoms. Studies have shown that incidence of rectal cancer can be 
reduced by two yearly stool occult blood testing and yearly flexible 
sigmoidoscopy. Other methods of screening are CT colonography, 
colonoscopy and fecal immunochemical testing (12). 
 
DIAGNOSIS OF COLORECTAL CANCER: 
 
The two modalities used in diagnosis of colorectal cancer are endoscopy and 
radiology. Colonoscopy is the diagnostic test which is most accurate since it 
can localise the lesion and biopsy it as well. Double contrast barium enema 
along with flexible sigmoidoscopy can also be used but it has a lower 
diagnostic yield as compared to colonoscopy. CT colonography is another 
diagnostic investigation (13,14).  
 
Rectal cancer is currently staged using the 7
th
 edition of the AJCC TNM 
classification (2010). Staging preoperatively is accomplished with CT or 
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MRI scan of the abdomen and pelvis and a chest X ray. Other investigations 
useful for locoregional evaluation of rectal cancer are rigid sigmoidoscopy, 
MRI and transrectal ultrasonography. An MRI scan is useful to assess the 
distance between the tumour and the mesorectal fascia, thereby predicting 
the likelihood of a positive circumferential resection margin. 
 
 
 
 
 
 
 
 
 
 
 
19 
 
 
7
th
 edition AJCC TNM classification 2010: 
 
 
Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades through the muscularis propria into the pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral peritoneum 
T4b Tumor directly invades or is adherent to other organs or structures 
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Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal 
tissues without regional nodal metastasis  
N2 Metastasis in 4 or more lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site (eg, liver, lung, ovary, nonregional node) 
M1b Metastases in more than 1 organ/site or the peritoneum 
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Tumour markers like carcinoembryonic antigen (CEA) and CA 19-9 have 
been associated with colorectal cancer. The diagnostic ability of these 
markers in the detection of colorectal cancer is not significant as they are 
non specific. However, in newly detected cancers, serum CEA levels have a 
prognostic ability (15,16).  
 
 
LOCAL EXCISION: 
 
Local excision allows removal of the tumour and surrounding tissue in one 
specimen. This permits assessment of margins, histology, vascular 
involvement and depth of invasion. However local excision is not an option 
for proximal and middle rectal tumours. The various options include 
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transanal excision, transanal endoscopic microsurgery, transsphincteric 
(York-Mason) procedure and transsacral (Kraske) procedure. There have 
been high rates of local recurrence after five years following these 
procedures and therefore are very rarely used in the treatment of rectal 
cancer (17,18). 
 
 
SPHINCTER SPARING PROCEDURES: 
 
Patients with invasive rectal cancers can be operated with sphincter sparing 
procedures provided the distal margins are histologically negative. The local 
recurrence rates of such procedures range from 6% to 31% (19) which are 
similar to abdominoperineal excision. Low anterior resection can be 
employed for tumours in the upper and middle third of the rectum. For distal 
rectal lesions a very low anterior resection is done. In very low and ultra low 
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anterior resections, the descending colon is anastomosed to the anal canal. In 
cases where there is a wide pelvis a colonic J pouch can be made (20).  
 
ABDOMINOPERINEAL EXCISION: 
 
 This procedure involves resection of the sigmoid colon, rectum and anal 
canal followed by the performance of a permanent colostomy. This, for 
many years was the gold standard for treatment of low rectal cancers against 
which sphincter sparing procedures and local excision procedures were 
compared. Local recurrence rates and five year survival rates did not differ 
significantly between abdominal perineal excision and sphincter sparing 
procedures (21). Quality of life on a long term basis was also similar to 
sphincter sparing procedures with the exception of depression related to 
body image changes (22). 
 
24 
 
However, with emerging evidence regarding the required distal resection 
margin and availability of stapling devices that facilitate a low anastomosis 
deep in the pelvis, it is less frequently performed for low rectal cancers and 
only reserved for situations where the pelvic floor or sphincter complex are 
involved. 
 
 
 
MULTIVISCERAL EXCISION: 
 
This includes resection of the cancer along with adjacent organs which are 
involved by cancer. A total pelvic exenteration involves en bloc removal of 
all pelvic organs. Modified exenterations can be posterior, anterior, 
supralevator or composite. This procedure is associated with high morbidity 
rates and reoperation rates (23). 
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CHEMORADIOTHERAPY AND RADIOTHERAPY – ADJUVANT AND 
NEOADJUVANT APPROACHES: 
 
The role of adjuvant therapy has been extensively studied in the treatment of 
rectal cancer, but no trial has unequivocally demonstrated improved overall 
survival with radiotherapy, despite a reduction in the rate of local recurrence.  
 
The Swedish Rectal Cancer Trial was the first randomized trial conducted to 
study the effect of pre operative radiotherapy on rates of local recurrence 
and overall survival in 1997. This trial had concluded that a short-term 
regimen of high-dose preoperative radiotherapy reduces rates of local 
recurrence and improves survival among patients with resectable rectal 
cancer (24). 
 In 2001, the Dutch Colorectal Cancer Group studied the effect of pre 
operative radiotherapy against surgery (total mesorectal excision) alone. The 
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conclusions of this trial were that short-term preoperative radiotherapy 
reduces the risk of local recurrence in patients with rectal cancer who 
undergo a standardized total mesorectal excision (25).  
 
In 2004, the German Rectal Cancer Trial group studied pre operative versus 
post operative chemoradiotherapy in the treatment of rectal cancer. This had 
shown that pre operative chemoradiotherapy decreased local toxicity and 
local recurrence rates but had no role in improving overall survival (26). 
 
 With improvements in surgical technique and histopathological assessment, 
the role of radiotherapy needed to be reassessed. This led to the MRC CR07 
trial which compared pre operative radiotherapy versus selective post 
operative chemoradiotherapy. This trial had shown that short course pre 
operative radiotherapy was effective in operable rectal cancer (27).  
The Polish Colorectal Study group compared pre operative short course 
radiotherapy against pre operative conventionally fractioned chemoradiation 
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in 2006. They concluded that there was no difference in survival, late 
toxicity or local control when compared to short course radiotherapy alone. 
However there was more early toxicity with short course radiotherapy (28). 
 
.Neoadjuvant chemoradiotherapy is generally considered for T3/T4 lesions. 
Studies have shown that neoadjuvant approach for these lesions has a more 
favourable toxicity profile and lower local recurrence rates when compared 
to adjuvant approaches. In cases of cT3N0 disease, upfront 
chemoradiotherapy has been questioned due to favourable low local 
recurrence rates after upfront surgery (29). Studies have shown that T3 
tumors with more than 5mm of extramural tumour invasion have a much 
higher chance of nodal involvement and therefore must be treated as high 
risk tumours. However data from the MERCURY trial suggest that the 
outcome in these patients may be good with surgery alone (30). The relative 
indication of chemoradiotherapy in T1/2 cancer is when MRI findings are 
suggestive of nodal disease. Neoadjuvant therapy may also be considered 
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when the tumour involves the mesorectal fascia or even is within 2mm of the 
fascia. This has a high predictive value of residual tumour in the 
circumferential resection margin (CRM) when total mesorectal excision is 
performed. Transrectal ultrasonography (TRUS) or high resolution MRI are 
the investigations of choice for locoregional staging. Prognosis of 
neoadjuvant chemoradiotherapy was predicted by the extent of post 
treatment tumour regression and the final stage based on the surgical 
specimen. Concurrent chemotherapy along with fractionation RT has 
become the standard regimen for the neoadjuvant approach (32). The 
optimal timing of surgery after neoadjuvant therapy is about 4-6 weeks. 
Patients who underwent preoperative chemotherapy did not appear to have 
more perioperative complications. 5 Fluorouracil forms the mainstay of 
chemotherapeutic regimen along with leucovorin, oxaliplatin and irinotecan 
used interchangeably. Bevacizumab, Cetuximab and Panitumumab ae 
humanized monoclonal antibodies that have been used recently (33). 
Radiation therapy with pelvic irradiation upto 45 Gy in 25 fractions by a 
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four field technique is given. For concurrent post operative 
chemoradiotherapy, infusional 5FU is preferred over bolus doses. Oral 
Capecitabine is accepted as a substitute for infusional 5FU. Options for 
chemotherapy are 5FU/LV and FOLFOX (5FU, Leucovorin and 
Oxaliplatin). 
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MORBIDITY FOLLOWING RECTAL RESECTION: 
 
Although the technique in rectal resection has largely been standardized and 
the anatomy elucidated, there remains a risk of failure and significant 
morbidity to the patient. The outcome following rectal resection is the result 
of a complex interaction between surgeon factors, patient factors and disease 
factors. Some of the factors that influence the outcome following an 
anastomosis are given below: 
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Surgeon Factors 
 
Patient Factors 
 
Disease Factors 
 
Intestinal blood supply Body mass index Inflammatory bowel disease 
Tension on the anastomosis Anesthesia severity assessment Metastatic carcinoma 
Perioperative hypoxia Age Radiation therapy 
Perioperative resuscitation Smoking Damage control surgery 
Intraoperative blood loss Nutritional status Emergent surgery/peritonitis 
Operative times Alcohol use Steroids 
  
Infraperitoneal location 
 
 
 
 
32 
 
Complications may include those that are common to any other intra 
abdominal operation such bleeding, infection, deep vein thrombosis, wound 
problems, pneumonia, myocardial infarction and renal failure. The 
complications specific to rectal resection are impotence in men (50% 
incidence), anastomotic leak (20% incidence), intra abdominal collection, 
urinary dysfunction and massive venous bleeding from the presacral space. 
It was conventionally believed that placement of a pelvic drain following 
rectal resection decreased the risk of post operative pelvic collection and 
also anastomotic leak. Recently performed studies have raised questios on 
the usefulness of closed pelvic drainage. However, there is no evidence 
strong enough to make a recommendation either in favour of or against 
closed pelvic drainage following rectal resection. 
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 This study was conducted in order to objectively establish the benefit of 
closed pelvic drainage in pelvic preventing pelvic complications following 
rectal resection for rectal cancer. 
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MATERIALS AND METHODS 
 
STUDY DESIGN: Prospective randomized controlled trial. 
 
INCLUSION CRITERIA: 
All patients undergoing elective rectal resection under General Surgery  
unit II (Colorectal), CMCH, Vellore. 
 
INTERVENTION AND COMPARATOR AGENT:  
Intervention: No pelvic drainage. 
Comparator: Closed pelvic drainage. 
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EXCLUSION CRITERIA: 
1. Patients operated on an emergency basis. 
2. Patients with disseminated disease where surgery is a palliative 
procedure. 
3. Patients with compromised immunity (on steroids, immunosupression, 
post transplant patients) 
4. Patients with intraoperative complications for which drainage is 
inevitable (spillage). 
 
METHOD OF RANDOMISATION: Block randomisation. 
 
METHOD OF ALLOCATION CONCEALMENT: In sealed envelopes. 
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PRIMARY OUTCOME:  
Detection of pelvic collection by means of pelvic ultrasonography done on 
the 5
th
 post operative day or earlier if clinically warranted and measurement 
of the volume if present. 
 
 
 
SECONDARY OUTCOMES:  
1. Postoperative stay in days (measured according to ‘fit for discharge’ 
criteria. 
2. Incidence of urinary tract infection (UTI) in the 4 weeks following 
surgery. 
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DURATION OF TRIAL: 
1.10.2011 to 30.6.2013  
 
 
SAMPLE SIZE CALCULATION: 
 
The sample size was calculated using the two proportion, equal allocation 
calculation with an alpha error of 5% and a power of 80%. 
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Proportion of collection in no drainage group   0.25    
Proportion of collection in  drainage group         0.10    
Estimated risk difference                           0.15    
Power (1- beta) %         80    
Alpha error (%)                                           5    
1 or 2 sided           2    
Required sample size for each arm              100   
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STATISTICAL ANALYSIS: 
Statistical analysis was done using the Chi square test and independent 
sample T test. 
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CONSORT 2010 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=70) 
Excluded  (n=10) 
   Not meeting inclusion criteria (n=8) 
   Declined to participate (n=2) 
   Other reasons (n=0) 
Analysed  (n= 31) 
 Excluded from analysis (give reasons) (n=0) 
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (give reasons) (n= 0) 
Allocated to intervention (n=31) 
 Received allocated intervention (n= 31) 
 Did not receive allocated intervention (give 
reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons) (n=0) 
Allocated to intervention (n=29) 
 Received allocated intervention (n=29) 
 Did not receive allocated intervention (give 
reasons) (n= 0) 
Analysed  (n=29) 
 Excluded from analysis (give reasons) (n=0) 
 
     Allocation 
        Analysis 
      Follow-Up 
Randomized (n=60) 
      Enrollment 
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ANALYSIS 
 
CATEGORICAL VARIABLES: 
 
Sex distribution: Out of the total of 60 patients, 45 were male and 15 were females.  
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MALE
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Fig. 1 showing sex distribution 
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SEX DISTRIBUTION AMONG THE TWO ARMS: 
In the intervention (drain) group 21 patients were males and 10 patients were 
females. 
In the no intervention (no drain) group, 24 were males and 5 were females. 
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   Drain 
Total    Drain No Drain 
 Male  21 24 45 
 67.7% 82.8% 75.0% 
Female  10 5 15 
 32.3% 17.2% 25.0% 
Total  31 29 60 
    
 
 
 
 
Table 1 showing sex demography between the two allocation groups 
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AGE DISTRIBUTION: 
The incidence of rectal cancer was seen mostly in the middle age group (40-60 
years) and the incidence was greater among males. (Fig. 2) 
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61-80
Male 
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Fig. 2 showing the age distribution of rectal cancer among males and females. 
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AGE DISTRIBUTION: 
The mean age among the two arms was comparable. 
 
 
 
 N Mean Std. Deviation 
Std. Error 
Mean 
 Drain 31 47.06 15.266 2.742 
No Drain 29 48.59 15.587 2.894 
 
 
 
 
Table 2 shows the mean ages in the two arms along with the standard 
deviation 
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DISTRIBUTION AMONG TWO ARMS ACCORDING TO DIAGNOSIS: 
Most patients were diagnosed with Carcinoma Rectum or Carcinoma rectosigmoid. 
Other diagnoses that were included were Familial Adenomatous Polyposis (FAP), 
Carcinoma anal canal and Tubulovillous adenoma (TVA).  
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Total    Drain No Drain 
 Carcinoma Recto Sigmoid  29 28 57 
 93.5% 96.6% 95.0% 
FAP  1 0 1 
 3.2% .0% 1.7% 
Carcinoma Anal Canal  0 1 1 
 .0% 3.4% 1.7% 
TVA  1 0 1 
 3.2% .0% 1.7% 
Total  31 29 60 
    
 
Table 3 showing distribution of patients between the two arms according to diagnosis 
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Fig. 3 showing distribution among the two arms according to diagnosis 
Ca rectum/rectosigmoid 
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DISTRIBUTION BETWEEN TWO ARMS ACCORDING TO TYPE OF 
SURGERY: 
There was equal distribution between the two arms among both the surgeries 
performed, Abdominal perineal excision (APE) and anterior resection (AR). 
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Fig. 4 showing distribution of surgeries among the two arms. 
APE (Abdominal perineal excision, AR (Anterior resection) 
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DRAIN NO DRAIN 
   APE 14 14 
AR 17 15 
Table 4 showing distribution of operations between the two arms 
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OUTCOME ANALYSIS 
 
PRIMARY OUTCOME (ANALYSIS OF POSTOPERATIVE PELVIC 
COLLECTION BETWEEN THE TWO ARMS):  
There was a trend towards lesser occurrence of pelvic collection in the group with 
no pelvic drainage (17.2% versus 29%) 
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Total 
   
No Collection 
Pelvic 
Collection 
 Drain  22 9 31 
 71.0% 29.0% 100.0% 
No Drain  24 5 29 
 82.8% 17.2% 100.0% 
Total  46 14 60 
 76.7% 23.3% 100.0% 
 
 
 
Table 5, showing the extent of pelvic collection between the two arms. 
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Fig.5 showing the distribution of pelvic collection between the two arms 
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MORBIDITY ASSESSMENT: 
INCIDENCE OF PELVIC COLLECTION ACCORDING TO THE TYPE OF 
OPERATION: 
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Fig. 6 showing the number of pelvic collection among the two arms according to 
type of surgery 
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EFFECT OF NEOADJUVANT CHEMOTHERAPY ON THE INCIDENCE OF 
PELVIC COLLECTION: 
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Fig. 7 showing the percentages of pelvic collection in the two arms and the 
reception of long course chemoradiation 
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TYPE OF INTERVENTION: 
 
 
 
 
 
 
 
 
 
 
 
 
DRAIN   
NO DRAIN  
  
 
  
No intervention 4 2 
Surgical 2 3 
Radiological 3 0 
Table 6 showing the type of intervention among the two arms 
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Fig. 8 showing the types of intervention in both the arms 
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ANASTOMOTIC LEAK RATES (Anterior resections): 
The number of anastomotic leaks in the drain arm were 5 out of 17 and in the ‘no 
drain’ arm were 3 out of 15. 
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Anastomotic leak
Fig.9 showing the number of anastomotic leaks among the two arms 
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 DRAIN NO DRAIN 
 
 
  
Anastomotic leak  5(29.4%) 3(20%) 
 
 
 
 
 
 
Table 7 showing the percentage of anastomotic leaks among the two 
arms 
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POST OPERATIVE STAY: 
Post operative stay was higher among patients in the ‘drain’ arm. 
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postop stay (in days)
Fig.9 showing the post operative stay in days among the two arms 
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OUTCOME DRAIN 
N = 31 
NO DRAIN 
N = 29 
P VALUE MEAN 
COLLECTION 9 
(29%) 
5 
(17.2%) 
0.281 11.8 
POSTOPERATIVE 
STAY 
9.68 8.52 0.476 1.160 
 
 
 
 
 
Table 7 showing both measurable outcomes with P values and mean differences in 
the two arms 
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The mean post operative stay in days was higher in the ‘drain’ arm. 
 
 
 
 N Mean Std. Deviation 
Std. Error 
Mean 
Postop stay Drain 31 9.68 6.508 1.169 
No Drain 29 8.52 5.980 1.110 
 
 
 
 
 
 
Table 8 showing the mean post operative stay in days between the two arms 
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SUMMARY OF OUTCOMES: 
 DRAIN (N=31) NO DRAIN(N=29) P VALUE 
COLLECTION 9 5 0.281 
ANASTOMOTIC 
LEAK 
5/17* 3/15* 0.588 
INTERVENTION 
REQUIRED 
5 3 0.856 
RADIOLOGICAL 3 0 - 
SURGICAL 2 3 0.103 
DURATION OF 
STAY 
9.68 8.52 0.456 
 
 
Table 9 showing the summary of outcomes with p values 
*Anterior resection only 
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RESULTS 
A total of 70 patients were enrolled into the trial, out of which 60 patients were 
randomised based on the inclusion criteria. 31 patients were allocated to the 
intervention (drain) arm and 29 patients were allocated to the no intervention arm 
(no drain).  
 
Out of the 60 patients, 45 were males which is consistent with international figures 
but more in favour of male sex (3:1 versus 1.06:1) The mean age overall was 47 
years. Prevalence among men was highest in the 41-60 age group and among 
women, prevalence was highest in the 21-40 age group. In the intervention (drain) 
group 21 patients were males and 10 patients were females. In the no intervention 
(no drain) group, 24 were males and 5 were females (Table 1). 
 
The two operations that were performed were abdominal perineal excision and 
anterior resection. The latter involved the performance of an anastomosis in the 
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pelvis. These operations were equally distributed among both the intervention arms 
(Fig.4) 
 
There was a trend towards fewer pelvic collection in the group with no pelvic 
drainage (17.2% versus 29%) (Fig.5 and Table 5). 
In the assessment of post operative morbidity (Fig.6), there was no significant 
difference in the incidence of pelvic collections according to the type of operation 
(abdominal perineal excision or anterior resection).  
According to Fig.6 the percentage of pelvic collections were higher in patients who 
underwent anterior resection in the ‘no drain’ arm and lesser in patients who 
underwent anterior resection in the ‘drain’ arm. 
In Fig.7, it was found that all the patients who had a pelvic collection in the ‘no 
drain’ arm underwent neoadjuvant therapy in the form of long course 
chemoradiation. One third of the patients in the ‘drain’ arm who had pelvic 
collection did not undergo any form of neoadjuvant therapy. 
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The method of intervention in the patients who had pelvic collections was mostly 
conservative in case of small collections and operative, if there was clinical 
deterioration of the patients’ condition. Three patients were managed with 
radiological drainage of the collection (Fig.8). However, operative intervention 
was higher in the ‘no drain’ group (Fig.9) (p value 0.15, 95%CI -0.9 – 0.14). 
 
The mean post operative stay in days was higher in the ‘drain’ arm. The difference 
between both the arms was 1.16 days (Table 9). 
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DISCUSSION 
 
Rectal surgery is associated with greater morbidity and mortality as compared to 
surgical procedures on other parts of the gastro intestinal tract. The risk for any 
surgical intervention can be assessed at four levels – the patient, the procedure, the 
provider and the anesthetic. In colorectal surgery the procedure by definition 
carries a high morbidity. Therefore most of the fast track recovery protocols are 
centered around the patient. Assessment of the risk preoperatively and optimization 
certainly decreases patient morbidity and mortality for an elective operation (34). 
 
Enhanced recovery after surgery (ERAS) or fast track pathways are multimodal 
approaches practiced in the perioperative period  in patients undergoing colorectal 
surgery. They are designed to improve the overall quality of care and reduce 
morbidity. The typical components of the enhanced recovery pathways include 
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appropriate patient selection, avoidance of bowel preparation unless indicated, pain 
management with multimodal approach including epidural catheter, using 
laparoscopic approach when possible, avoidance of excess fluid infusion, early 
initiation of diet, ambulation and adherence to SCIP (surgical care improvement 
project) protocols.  
 
However, anastomotic drainage has been a long standing controversy. Routine 
drainage is not a component of the ERAS pathways. Meta-analysis of trials have 
been unsuccessful in showing benefit of routine drainage. It has been 
recommended that drain placement should however not interfere with a standard 
fast track protocol if clinically indicated (35).  
 
In the present trial, out of the 60 patients recruited, incidence of rectal cancer was 
found to be higher in males by three times which is much higher compared to the 
international figures. 
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The mean age of occurrence was found to be 47 years which is much lower than 
the SEER(Surveillance Epidemiology and End Results) data from the United 
States where the mean age was found to be 69 years. This is consistent with other 
Indian data which has shown increased incidence of rectal cancer among young 
males (2). 
 
The two main operations that were performed for rectal cancer were abdominal 
perineal excision and anterior resection depending on the situation of the tumour 
and the possibility of obtaining free margins without sacrificing the sphincter. 
Greater morbidity is expected with an anterior resection as it involves the 
performance of an anastomosis in the pelvis. The vascularity of the anastomosis is 
further jeopardised due to the preoperative radiation therapy. 
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The incidence of pelvic collection was found to be higher in the ‘drain’ arm (20% 
vs 17%), although this difference was not statistically significant. This finding has 
also been complemented with longer hospital stays associated with the drain group.  
 
There were no significant results obtained from the morbidity assessment but all 
the measurements were pointing towards greater morbidity associated with routine 
pelvic drainage. Moreover, the incidence of pelvic collections did not depend much 
upon the type of operation. This meant that performance of an anastomosis in the 
pelvic (anterior resection) in the absence of confounding factors, did not increase 
the incidence of a pelvic collection. However, it would be too early to arrive at 
such a conclusion without adequate sample size. 
 
Most patients received neoadjuvant therapy in the form of long course 
chemoradiation. This involved radiotherapy with 50.4Gy in 28 fractions and 
chemotherapy with 5-Fluorouracil or Capecitabine with or without oxaliplatin and 
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leucovorin rescue. This certainly had an impact on the post operative outcome. All 
patients with a pelvic collection in the ‘no drain’ arm received some form of 
neoadjuvant therapy which showed that it was a significant contributing factor in 
determining the post operative outcome. Interestingly, in the ‘drain’ arm, three 
patients (33.3%) who did not have any form of neoadjuvant therapy, had a post 
operative pelvic collection. This suggested that in the presence of a pelvic drain 
there was greater chance of developing a post operative pelvic collection 
irrespective of undergoing chemoradiation. 
 
Out of the 14 patients who had a pelvic collection, 5 underwent re-exploration in 
the form of a laparotomy and wash out of the collection. 6 patients were managed 
conservatively and 3 patients underwent radiological drainage of the abscess. 
Therefore, in hemodynamically stable patients, not showing features of systemic 
inflammatory response, it is prudent to proceed with a non-operative line of 
management. 
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Out of all the study patients, there was only one patient who was readmitted with 
urinary tract infection within 30 days of the operation. Due to the lack of 
substantiality, this data was not analysed.  
 
Certain patients in both the arms required definitive drainage inspite of being 
randomised to the ‘no drain’ arm due to intraoperative course that warrante 
drainage. These patients were included in the study as they were randomised with 
an intention to treat. 
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CONCLUSIONS 
 
The aim of conducting this study was to establish a definitive association between 
the routine use of closed tube drainage of the pelvis in patients undergoing 
resection for rectal cancer. The paucity of data in this area and the equivocal results 
of existing studies further warranted the need for this study. 
 
Although the study was not carried on till the complete sample size was reached, 
the results were all consistent and showed trends in the same direction. However, 
statistically significant conclusions cannot be drawn from the analysis of the 
results. The duration of the study and the time constraint is one of the major 
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limitation of this study. Apart from this, sensitivity of a pelvic ultrasonogram, 
observer bias and the inability to perform blinding are the other limitations. 
 
The increased incidence of rectal cancer among younger males has stood out in this 
study which is in contrast with studies from the western population. 
 
The use of pelvic drainage has not shown to drastically contribute towards 
reducing post operative morbidity in terms of decreased pelvic collections or 
reduced hospital stays. Infact, the absence of a pelvic drain has shown a trend 
towards reduced incidence of pelvic collection and reduced hospital stay. 
However, these results are not statistically significant. 
 
The other factor that contributed to the outcome of these patients was neoadjuvant 
therapy in the form of long course chemoradiation. 
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The lack of unequivocal evidence in the benefit of routine pelvic drainage has 
shown that it is a questionable intervention. 
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CONSENT FORM 
Informed consent form to participate in the study: 
 
 
Study Title: Randomised trial of assessing morbidity in patients undergoing 
surgery for rectal cancer. 
Subject Initials:                           Subject name: 
Date of birth/Age: 
1. I confirm that I have read and understood the patient information sheet dated 
_____ for the above study and have had the opportunity to ask questions [ ] 
2. I understand that my participation in the study is voluntary and that I am free to 
withdraw at anytime , with out giving any reason, with out my medical care  or 
legal rights being affected [ ] 
3. I understand that the sponsor of the clinical trial, others working on the 
Sponsor's behalf, the Ethics committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and 
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any further research that may conducted in relation to it, even if I withdraw from 
the trial, I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [ ] 
4. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [ ] 
5. I  agree to take part in the above study. [ ] 
 
 
 
Signature (or thumb impression) of the subject/ legally acceptable representative: 
date: 
Signatory's name: 
 
 
Signature of the investigator: 
Date: 
85 
 
Study investigator's name: 
 
 
Signature of the witness: 
Date: 
Name of the witness: 
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PROFORMA: 
 
 
 
 
S.No Name Age Sex Diagnosis Surgery Drain Collection Postop  
stay 
Comp 
          
          
          
 
